10-Q quarterly report · filed Nov 5, 2026

HAEMONETICS CORP (HAE) Q3 2026 10-Q Quarterly Report

Short answer

HAEMONETICS CORP (HAE) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 26, 2026. Quarterly revenue was $358M (up 9.3% year over year) with net income of $46M.

Q3 2026 key financials · XBRL

Revenue
$358M
+9.3% YoY · +5.4% QoQ
Net income
$46M
+19.7% YoY · +40.3% QoQ
Operating margin
21.0%
Gross margin
61.7%
EPS (diluted)
$1.00
+23.5% YoY · +38.9% QoQ

Source: XBRL data from the HAEMONETICS CORP (HAE) Q3 2026 10-Q on SEC EDGAR. USD.

HAEMONETICS CORP Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $357.8M, up 9.3% YoY from $327.3M
  • Operating margin 21.0% vs 17.9% YoY, net margin 12.9% vs 11.8%
  • Best performer: Plasma revenue $162.6M, up 16.5%; worst: Interventional Technologies $60.5M, up 2.4%
  • Cash $260.7M vs $245.4M; operating cash flow $180.4M vs $128.7M for six months
  • $100.0M revolving-credit repayment; CSL rollout expected by end of calendar year 2027, timing subject to change

Risk Factors

  • No material changes from the fiscal 2026 Form 10-K risk factors
  • Carried-forward risks remain unchanged, with no new triggers identified

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other HAEMONETICS CORP quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.